Benzinga | Aug 27, 2020 08:12AM EDT

Cortexyme Announces Issuance Of Composition Of Matter Patent For Atuzaginstat By The US Patent And Trademark Office

- New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388)

- The '826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term extension of up to an additional five years

Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,730,826 relating to Cortexyme's lead small molecule, atuzaginstat (COR388).

Cortexyme's '826 patent provides additional composition of matter protection for atuzaginstat and gingipain inhibitors, with additional claims pending in related applications. The patent is expected to provide patent protection for atuzaginstat through September 2037, not including a possible patent term extension of up to five years as provided under the Drug Price Competition and Patent Restoration Act (35 U.S.C. ?156).

Casey Lynch, Cortexyme's chief executive officer, co-founder, and chair commented: "We are particularly excited about the issuance of this composition of matter patent for atuzaginstat in anticipation of upcoming results from our GAIN Phase 2/3 clinical trial in the fourth quarter of 2021. The USPTO's issuance of this patent strengthens our intellectual property protection for gingipain inhibitors and atuzaginstat. This patent further supports our ongoing R&D efforts to develop treatments for Alzheimer's and other degenerative diseases and supports the potential expansion of our pipeline into additional indications."